Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta-previously-anorohttps://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta-previously-anoro
Retrieved on: 
星期二, 一月 2, 2024
Information
Tags: 
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, Blood, International, Chronic obstructive pulmonary disease, Cough, Bromide, Common, Headache, Nose, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device
Geotags: 
EU
摘要
Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Copyright: 
2024 European Medicines Agency. All Rights Reserved.